Meta‑analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk

Chen,Weifeng; Wu,Qianlan; Ren,Hongbo

doi:10.3892/br.2013.181

Meta‑analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk

Authors:
- Weifeng Chen
- Qianlan Wu
- Hongbo Ren
View Affiliations

Affiliations: Department of Neurosurgery, Central Hospital of Handan, Handan, Hebei 056000, P.R. China, Graduate School of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: October 7, 2013 https://doi.org/10.3892/br.2013.181
Pages: 105-111

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidemiological studies have been conducted to evaluate genetic variations of murine double minute 2 (MDM2) SNP309 associated with the risk of gastric cancer (GC), although evidence remains conflicting. To gain a better understanding of this relationship, a meta‑analysis was performed. Several electronic databases were searched up to February 2013, in order to identify relevant case‑control studies. Seven published case‑control studies with 2,199 cases and 3,201 controls were included. In the overall analysis, significant associations between the MDM2 SNP309 variant and GC risk were found for G vs. T alleles (OR=1.35; 95% CI, 1.24‑1.47), GG vs. TT (OR=1.88; 95% CI, 1.59‑2.24), recessive model (OR=1.71; 95% CI, 1.49‑1.96). Furthermore, stratified by cancer site, significant associations were observed in gastric cardia cancer for all the models, although no significant association was found in any of the models among non‑gastric cardia cancer, with the exception of the recessive model. In the subgroup analysis by source of control, MDM2 SNP309 was associated with increased GC risk for the hospital‑based case‑control (HCC) study for the GG vs. TT, recessive model and for the population‑based case‑control (PCC) study for the GG vs. TT, recessive model. Following stratification by gender and infection status of Helicobacter pylori (HP) for the recessive model, a significant association was found only in the HP‑positive infected individuals. However, no statistically significant association was observed in males, females or the HP‑negative infected individuals. In summary, the association between MDM2 SNP309 and GC risk was statistically significant, particularly in gastric cardia cancer for the HP‑positive population group.

View Figures

View References

1	Nakao M, Matsuo K, Ito H, et al: ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infection. Cancer Epidemiol Biomarkers Prev. 20:1665–1672. 2011. View Article : Google Scholar : PubMed/NCBI
2	Duell EJ, Travier N, Lujan-Barroso L, et al: Alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr. 94:1266–1275. 2011. View Article : Google Scholar
3	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ebert MP, Niemeyer D, Deininger SO, et al: Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res. 5:2152–2158. 2006. View Article : Google Scholar : PubMed/NCBI
5	Cahilly-Snyder L, Yang-Feng T, Francke U and George DL: Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet. 13:235–244. 1987. View Article : Google Scholar : PubMed/NCBI
6	Fakharzadeh SS, Trusko SP and George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565–1569. 1991.PubMed/NCBI
7	Piette J, Neel H and Marechal V: Mdm2: keeping p53 under control. Oncogene. 15:1001–1010. 1997. View Article : Google Scholar : PubMed/NCBI
8	Chen H, Xie L and Liu B: Clinical significance of MDM2 as a tumor biomarker. Chin-Ger J Clin Oncol. 11:356–360. 2012. View Article : Google Scholar
9	Picksley SM and Lane DP: The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays. 15:689–690. 1993. View Article : Google Scholar : PubMed/NCBI
10	Hirata H, Hinoda Y, Kikuno N, et al: MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 13:4123–4129. 2007. View Article : Google Scholar : PubMed/NCBI
11	Terry K, McGrath M, Lee IM, Buring J and De Vivo I: MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 17:983–986. 2008. View Article : Google Scholar : PubMed/NCBI
12	Olsson H, Hultman P, Rosell J, Söderkvist P and Jahnson S: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol. 13:52013. View Article : Google Scholar : PubMed/NCBI
13	Zhang GX, Li YQ and Pan XL: Polymorphism of MDM2 promoter, regulated by helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility to gastric carcinoma and poor prognosis in Chinese patients. J Gastroenterol Hepatol. 26:2802011.
14	Wang X, Yang J, Ho B, et al: Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter. 14:114–119. 2009.
15	Cho YG, Choi BJ, Song JH, et al: No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma. 55:256–260. 2008.PubMed/NCBI
16	Egger M and Smith GD: Bias in location and selection of studies. BMJ. 316:61–66. 1998. View Article : Google Scholar : PubMed/NCBI
17	Pan X, Li Y, Feng J, et al: A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients. BMC Cancer. 13:1262013.PubMed/NCBI
18	Li Z: Association of gene polymorphisms with helicobater pylori related gastric cancer in a Chinese population. (unpublished masters thesis). 2011
19	ERL, Zhang L, Niu W, et al: Relevance of MDM2 polymorphisms with esophageal squamous cell carcinoma, gastric adenocarcinoma and double primary cancers in esophagus and stomach. Mod Prev Med. 39:33422012.
20	Er L, Zhang L, Niu W, et al: Relation of MDM2 gene polymorphism and Helicobacter pylori infection to gastric cardiac carcinoma. Clin Focus. 24:1594–1597. 2009.
21	Cao YY, Zhang XF, Guo W, Wang R, Ge H and Zhang JH: Association of the MDM2 polymorphisms with susceptibility of esophageal squamous cell carcinoma and that of gastric cardiac adenocarcinoma. Tumor. 27:628–632. 2007.
22	Yang M, Guo Y, Zhang X, et al: Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis. 28:1996–2001. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ohmiya N, Taguchi A, Mabuchi N, et al: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 24:4434–4440. 2006. View Article : Google Scholar : PubMed/NCBI
24	González CA and Agudo A: Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go. Int J Cancer. 15:745–753. 2012.PubMed/NCBI
25	Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA and Levine AJ: MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet. 43:950–952. 2006. View Article : Google Scholar : PubMed/NCBI
26	Ma HB, Huang T, Han F and Chen WY: Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev. 13:2841–2846. 2012. View Article : Google Scholar : PubMed/NCBI
27	Ma YY, Guan TP, Yao HB, et al: The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls. PLoS One. 8:e550192013.
28	Zhang Y, Bai Y, Zhang Y, Guan J and Chen L: The MDM2 309 T/G polymorphism is associated with head and neck cancer risk especially in nasopharyngeal cancer: a meta-analysis. Onkologie. 35:666–670. 2012. View Article : Google Scholar : PubMed/NCBI
29	Zhuo W, Zhang L, Zhu B, Ling J and Chen Z: Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PLoS One. 7:e415462012. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Zheng Y, Lei D, et al: MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev. 12:1899–1903. 2011.
31	Economopoulos KP and Sergentanis TN: Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 120:211–216. 2010. View Article : Google Scholar : PubMed/NCBI
32	Wiseman M: The Second World Cancer Research Fund/American Institute for Cancer. Proc Nutr Soc. 67:253–256. 2008. View Article : Google Scholar
33	He W, Long J, Xian L, et al: MDM2 SNP309 polymorphism is associated with lung cancer risk in women: a meta-analysis using METAGEN. Exp Ther Med. 4:569–576. 2012.PubMed/NCBI
34	Kodama M, Fujioka T, Murakami K, et al: Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J Gastroenterol Hepatol. 20:941–946. 2005.